Publications & presentations

Every peer-reviewed paper, erratum, supplement and conference poster, each with its own indexable page and citation metadata.

33 items

All publications and presentations

May 2026
Perspective
Restoring Regulatory Fairness and Reclaiming Biomedical Leadership: ALS, Rare Disease Regulation, and the Future of Regenerative MedicineJournal of the Academy of Public HealthView source
April 2024
Peer-reviewed
Debamestrocel multimodal effects on biomarker pathways in amyotrophic lateral sclerosis are linked to clinical outcomesMuscle & NerveView source
September 2022
Peer-reviewed
Evaluation of neurotrophic factor secreting mesenchymal stem cells in progressive multiple sclerosisMultiple Sclerosis JournalView source
August 2022
Peer-reviewed
Erratum to: A randomized placebo-controlled Phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosisMuscle & NerveView source
August 2022
Supplement
Supplemental file with updated graphs from the ErratumMuscle & NerveView source
December 2021
Peer-reviewed
A randomized placebo-controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosisMuscle & NerveView source
October 2021
Presentation
Therapeutic benefits of MSC-NTF (NurOwn®) exosomes in acute lung injury models2021 NYSCF ConferenceView source
October 2021
Presentation
CSF biomarker correlations with primary outcome in NurOwn Phase 3 clinical trial2021 Annual NEALS MeetingView source
January 2021
Peer-reviewed
MSC-NTF (NurOwn) exosomes: a novel therapeutic modality in the mouse LPS-induced ARDS modelStem Cell Research & TherapyView source
August 2020
Peer-reviewed
Effects of MSC-NTF cells on T and B regulatory cell function in ALSAmyotrophic Lateral Sclerosis and Frontotemporal DegenerationView source
November 2019
Peer-reviewed
NurOwn, phase 2, randomized, clinical trial in patients with ALSNeurologyView source
May 2019
Presentation
Phase 2 open-label, multicenter study of repeated intrathecal administration of autologous MSC-NTF cells in progressive multiple sclerosis2019 Annual CMSC MeetingView source
May 2019
Presentation
Molecular characterization of VEGF secretion by MSC-NTF cells (NurOwn): therapeutic implications in ALS2019 Annual AAN MeetingView source
May 2019
Presentation
Modulation of CSF caspase-3 in MSC-NTF cells (NurOwn) in a Phase 2 ALS study: correlations with CSF biomarkers and clinical response2019 Annual AAN MeetingView source
December 2018
Presentation
A systematic review of enrichment strategies for current clinical trials in ALSInternational Symposium on ALS/MNDView source
October 2018
Presentation
MicroRNA changes in the NurOwn Phase 2 ALS randomized clinical trial: relationship to neuroprotection and innate immunityAnnual NEALS ConferenceView source
April 2018
Presentation
Modulation of CSF miRNAs in ALS Phase 2 study participants treated with MSC-NTF cells (NurOwn)Annual AAN MeetingView source
April 2018
Presentation
NurOwn Phase 2 ALS trial: ALSFRS-R improvement is reflected in subscale domainsAnnual AAN MeetingView source
November 2017
Peer-reviewed
miRNA profiling of NurOwn: mesenchymal stem cells secreting neurotrophic factorsStem Cell Research & TherapyView source
2017
Peer-reviewed
Long term beneficial effect of neurotrophic factors-secreting mesenchymal stem cells transplantation in the BTBR mouse model of autismBehavioural Brain ResearchView source
2017
Peer-reviewed
Concise review: mesenchymal stem cells in neurodegenerative diseasesStem CellsView source
January 2016
Peer-reviewed
Safety and clinical effects of mesenchymal stem cells secreting neurotrophic factor transplantation in patients with amyotrophic lateral sclerosisJAMA NeurologyView source
2014
Peer-reviewed
Safety of repeated transplantations of neurotrophic factors-secreting human mesenchymal stromal stem cellsClin Transl MedView source
2014
Peer-reviewed
Rare combination of myasthenia and motor neuronopathy, responsive to MSC-NTFstem cell therapyMuscle NerveView source
2012
Peer-reviewed
Intrastriatal transplantation of neurotrophic factor-secreting human mesenchymal stem cells improves motor function and extends survival in R6/2 transgenic mouse model for Huntington’s diseasePLoS CurrView source
2012
Peer-reviewed
Mesenchymal stem cells induced to secrete neurotrophic factors attenuate quinolinic acid toxicity: a potential therapy for Huntington’s diseaseExp NeurolView source
2012
Peer-reviewed
Differentiated mesenchymal stem cells for sciatic nerve injuryExp NeurolView source
2010
Peer-reviewed
Intravitreal injections of neurotrophic factors secreting mesenchymal stem cells are neuroprotective in rat eyes following optic nerve transectionInvest Ophthalmol Vis SciView source
2009
Peer-reviewed
Intracerebroventricular transplantation of human mesenchymal stem cells induced to secrete neurotrophic factors attenuates clinical symptoms in a mouse model of multiple sclerosisJ Mol NeurosciView source
2009
Peer-reviewed
Protective effects of neurotrophic factor-secreting cells in a 6-OHDA rat model of Parkinson diseaseStem Cells and DevelopmentView source
2009
Peer-reviewed
Adult neurotrophic factor-secreting stem cells: a potential novel therapy for neurodegenerative diseasesIsr Med Assoc JView source
2009
Peer-reviewed
Induction of adult human bone marrow mesenchymal stromal cells into functional astrocyte-like cells: potential for restorative treatment in Parkinson’s diseaseJ Mol NeurosciView source
2008
Peer-reviewed
Migration of neurotrophic factors-secreting mesenchymal stem cells toward a quinolinic acid lesion as viewed by magnetic resonance imagingStem CellsView source

BrainStorm's autologous MSC-NTF cell therapy (NurOwn^®, debamestrocel) is investigational and has not been approved by the FDA or any other regulatory authority.